Core Viewpoint - Cue Biopharma, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $12.0 million before expenses [1]. Group 1: Offering Details - The offering includes 11,564,401 shares of common stock and warrants for 2,891,100 shares, as well as pre-funded warrants for 12,435,599 shares and accompanying warrants for 3,108,900 shares [1]. - The combined public offering price for each common stock and warrant is $0.50, while the pre-funded warrants are priced at $0.499 [1]. - The offering is expected to close around September 30, 2024, pending customary closing conditions [1]. Group 2: Management and Structure - Oppenheimer & Co. Inc. is the sole book-running manager, with Newbridge Securities Corporation acting as co-manager for the offering [2]. - Cue Biopharma is led by an experienced management team and independent Board of Directors with expertise in immunology and immuno-oncology [6]. Group 3: Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics to engage and modulate disease-specific T cells [5]. - The company's proprietary platform, Immuno-STAT™, aims to harness the immune system's potential without broad systemic immune modulation [5].
Cue Biopharma Announces Pricing of $12.0 Million Public Offering